Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases.

Our vision is to make precision medicine available to physicians and patients for the treatment of cancers and other difficult-to-treat diseases.

We are working to provide clinicians with an accurate and improved way to select the patients who may receive the greatest benefit from a particular therapy. Because our values are founded on improving the health of patients, we strive to achieve targeted drug delivery to diseased cells to improve effectiveness of therapy and reduce undesirable side effects.

West Lafayette, US
Size (employees)
76 (est)-2%
Endocyte was founded in 1995 and is headquartered in West Lafayette, US

Key People at Endocyte

Mike A. Sherman

Mike A. Sherman


Endocyte Office Locations

Endocyte has an office in West Lafayette
West Lafayette, US (HQ)
3000 Kent Avenue

Endocyte Metrics

Endocyte Financial Metrics

Revenue (2016)

$70 k

Net income (2016)

($43.9 m)

Market capitalization (21-Mar-2017)

$98.1 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$31.2 m
Endocyte's current market capitalization is $98.1 m.
Endocyte's revenue was reported to be $70 k in FY, 2016
FY, 2013FY, 2014FY, 2015FY, 2016


$64.9 m$70.4 m$70 k$70 k

Revenue growth, %


Operating expense total

$83.2 m$65.3 m$42 m$44.8 m


($18.3 m)$5 m($42 m)($44.7 m)

EBIT margin, %


Interest expense

$2.5 k$1.2 k

Interest income

$465.5 k$578.6 k

Net Income

($18 m)$5.5 m($41.3 m)($43.9 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$52.8 m$45.5 m$15.4 m$31.2 m

Accounts Receivable


Current Assets

$133.3 m$127 m$174.9 m$140.3 m


$3.8 m$4 m$3.4 m$3.2 m

Total Assets

$162.9 m$212.8 m$178.4 m$143.5 m

Accounts Payable

$5.4 m$1.2 m$1.3 m$1.4 m

Current Liabilities

$73.7 m$6.9 m$6.2 m$5.6 m

Additional Paid-in Capital

$262.1 m$373.6 m$381.1 m$390.8 m

Retained Earnings

($173.9 m)($168.5 m)($209.7 m)($253.6 m)

Total Equity

$205 m$171.3 m$137.1 m

Financial Leverage

1 x1 x1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($18 m)$5.5 m($41.3 m)($43.9 m)

Depreciation and Amortization

$674.7 k$857.1 k$886.7 k

Accounts Receivable


Accounts Payable

($386.2 k)($3.7 m)($60.7 k)$1.4 m

Cash From Operating Activities

($51.1 m)($42.2 m)($32.2 m)

Purchases of PP&E

($827.8 k)($1.5 m)($341.6 k)

Cash From Investing Activities

$69.3 m($68.6 m)$1.5 m

Endocyte Market Value History

Endocyte Company Life

You may also be interested in